Budd-Chiari syndrome;Syndrome de Budd-Chiari

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 10, 2006, Pages 1162-1169

  Plessier, Aurélie ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; CONTRACEPTIVE AGENT; DACARBAZINE; FIBRINOLYTIC AGENT;

ANGIOPLASTY; BUDD CHIARI SYNDROME; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; HUMAN; LIVER ANGIOGRAPHY; LIVER BIOPSY; LIVER VEIN THROMBOSIS; MEDICAL RESEARCH; MYELOPROLIFERATIVE DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL CONTRACEPTION; PORTAL HYPERTENSION; RADIODENSITOMETRY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPLENOMEGALY; THROMBOGENESIS;

EID: 33750601496     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(06)73495-9     Document Type: Review

References (38)

1. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76.
2. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003;38:364-71.
3. EN-Vie consortium. Guidelines for the management of BCS, 2004 : http://www.envie-project.org/index.html.
4. Ludwig J, Hashimoto E, McGill D, Heerden Jv. Classification of hepatic venous outflow obstruction:ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc 1990;6
5. Parker RGF. Occlusion of the hepatic veins in man. Medicine (Baltimore) 1959;38:369-402.
6. Hadengue A, Poliquin M, Vilgrain V, Belghiti J, Degott C, Erlinger S, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 1994;106:1042-7.
7. Panis Y, Belghiti J, Valla D, Benhamou JP, Fekete F. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery 1994;115:276-81.
8. Valla D, Benhamou JP. Obstruction of the hepatic veins or suprahepatic inferior vena cava. Dig Dis 1996;14:99-118.
9. Cazals-Hatem D, Vilgrain V, Genin P, Denninger MH, Durand F, Belghiti J, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology 2003;37:510-9.
10. Vilgrain V, Lewin M, Vons C, Denys A, Valla D, Flejou JF, et al. Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology 1999;210:443-50.
11. Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001;48:264-268.
12. Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol 2003;39:496-501.
13. Deniè C, Zeitoun G, Azar N, El Younsi M, Hadengue A, Boudet MJ, et al. Acute Budd-Chiari syndrome:spontaneously reversible exacerbation of hepatocellular necrosis but bad long term prognosis. Hepatology 1995;22:253A.
14. Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994;73:21-36.
15. Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500-8.
16. Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis 2002;22:15-26.
17. Okuda K. Membranous obstruction of the inferior vena cava: etiology and relation to hepatocellular carcinoma. Gastroenterology 1982;82:376-9.
18. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587-91.
19. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005;129:553-60. 20.
20. Denninger MH, Beldjord K, Durand F, Denie C, Valla D, Guillin MC. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995;345:525-6.
21. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005;2:2.
22. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
23. Pelletier S, Landi B, Piette JC, Ekert P, Coutellier A, Desmoulins C, Fadlallah JP, Herson S, Valla D. Antiphospholipid syndrome as the second cause of non-tumorous Budd-Chiari syndrome. J Hepatol 1994;21:76-80.
24. Ugo V, James C, Vainchenker W. [A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]. Med Sci (Paris) 2005;21:669-70.
25. Urano Y, Ohmori H, Sugimura H, Fukushima T. [Behcet's disease with Budd-Chiari syndrome. Apropos of a case. Review of cases autopsied in Japan and of the literature]. Ann Pathol 1986;6:192-6.
26. Valla D, Dhumeaux D, Babany G, Hillon P, Rueff B, Rochant H, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd- Chiari syndrome. Gastroenterology 1987;93:569-75.
27. Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986;90:807-11.
28. Raj K, Patel NL, Heneghan MA, Westwood N, Milojkovic D, Thanigaikumar K, et al. Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome. Blood 2005;106:2588 [Abstract].
29. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor V leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with budd-chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-8.
30. Bismuth E, Hadengue A, Hammel P, Benhamou JP. Hepatic vein thrombosis in Behcet's disease. Hepatology 1990;11:969-74.
31. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 2003;38:793-803.
32. Barrault C, Plessier A, Valla D, Condat B. [Non surgical treatment of Budd-Chiari syndrome: a review]. Gastroenterol Clin Biol 2004;28:40-9.
33. Perello A, Garcia-Pagan JC, Gilabert R, Suarez Y, Moitinho E, Cervantes F, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002;35:132-9.
34. Mancuso A, Fung K, Mela M, Tibballs J, Watkinson A, Burroughs AK, et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol 2003;38:751-4.
35. Hernandez-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004;40:1197-202.
36. Srinivasan P, Rela M, Prachalias A, Muiesan P, Portmann B, Mufti GJ, et al. Liver transplantation for Budd-Chiari syndrome. Transplantation 2002;73:973-7.
37. Langlet P, Escolan S, Zeitoun G, Mallet A, Vinel JP, Belghiti J, et al. Validation of prognostic factors and reeavluation of portosystemic shunting in Budd-Chiari syndrome. Hepatology 1998;28:450A.
38. Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999;30:84-9.